Huiya Wu, a partner in Goodwin's IP Litigation practice, is a member of the firm’s Life Sciences Disputes group and is an intellectual property litigator who has spent more than 20 years litigating and trying cases in both federal and state courts, and has appeared before the Patent and Trademark Office (PTO), the Patent Trial and Appeal Board (PTAB), as well as the International Trade Commission (ITC). She has represented clients in a wide range of technologies, including pharmaceuticals, analytical devices, medical devices, automotive parts, and internet business methods, and has particular expertise in litigation under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act.
Huiya has been recognized in Intellectual Asset Management’s Patent 1000, an annual listing of the world’s leading patent practitioners, in which clients have described her as “super-clever, highly persuasive and thoughtful,” “a top-notch advocate and trusted adviser who helps you achieve your key business objectives,” and having “first-rate technical expertise and an appealing and effective courtroom presentation manner,” and “an excellent attorney who can always be trusted to put her clients’ needs first.”
She has an active pro bono practice, including her work with the Legal Services NYC, Project Citizenship, Joyful Heart Foundation, and My Sisters’ Place, and is a recipient of the New York City Bar Association’s Thurgood Marshall Award for her work defending individuals in capital punishment cases. She also currently serves as co-chair of Goodwin’s Women’s Initiative.
Highlights of Huiya’s work includes representing:
- Amneal Pharmaceuticals, in currently pending patent infringement cases, one involving a generic formulation of vasopressin injection, and another involving a generic formulation of dimethyl fumarate. Par Pharmaceutical et al. v. Amneal et al. (D. Del.); Biogen v. Amneal et al. (D. Del.)
- Fresenius Kabi, in an inter partes review proceeding involving a patent on purification processes for proteins expressed in non-mammalian systems. Fresenius Kabi et al. v. Amgen et al. (PTAB)
- Celltrion, in parallel BPCIA patent infringement and inter partes review proceedings involving Celltrion’s biosimilar to Rituxan. Genentech v. Celltrion (D.N.J./PTAB)
- Sun Pharmaceutical, as lead counsel at trial in a patent infringement case involving a generic drug product to treat rosacea. Case settled favorably. Galderma et al. v. Sun Pharmaceutical et al. (D. Del.)
- Taro Pharmaceuticals, as lead counsel in parallel patent infringement and inter partes review proceedings involving a generic drug product used to treat iron overload caused by blood transfusions. Case settled favorably after expert discovery. ApoPharma et al. v. Taro Pharmaceuticals et al. (E.D. Tex./PTAB)
- Torrent Pharmaceuticals, in a successful challenge before the PTAB, in filing an inter partes review petition on an Orange-Book-listed patent relating to formulations for treating multiple sclerosis. Torrent Pharmaceuticals et al. v. Novartis et al. (PTAB)
- Glenmark Pharmaceuticals, as second-chair counsel at trial and appeal in a patent infringement case involving a generic gel drug product to treat rosacea. Intendis GmbH et al. v. Glenmark Pharmaceuticals et al. (D. Del.)
- Cipla, as lead counsel in a patent infringement case involving eye drops to treat ocular itching associated with allergies. Case settled favorably. Alcon Research et al. v. Cipla Limited et al. (S.D. Ind.)
- Tris Pharma, in a trade secret case involving a prescription cough syrup, in which the court denied UCB’s motion for a preliminary injunction and subsequently granted summary judgment in favor of Tris Pharma on UCB’s trade secret claims. UCB Manufacturing v. Tris Pharma et al. (New Jersey state court)
- Robert Bosch in a patent infringement case before the ITC related to windshield wipers, which settled favorably. In the Matter of Certain Wiper Blades (ITC)
- Boston Scientific at trial and on appeal in a patent infringement case related to stents, which settled favorably. Cordis Corp. v. Boston Scientific Corp. et al. (D. Del.)
- Applied Biosystems at trial and on appeal in a patent infringement case related to mass spectrometers. The Federal Circuit affirmed jury verdict of $47.5 million, the fourth-largest jury verdict in an intellectual property case that year. Applied Biosystems et al. v. Micromass UK Ltd. et al. (D. Del.)
Huiya is a member of the New York State Bar Association, the New York Intellectual Property Law Association, and the American Intellectual Property Law Association.
Prior to joining Goodwin in 2014, Huiya was a partner at Kenyon & Kenyon in New York City, where she was a member of that firm’s Associates Committee and Diversity Committee. She currently serves on the Women@Goodwin Committee, which actively supports the firm's goals to attract, retain, develop and advance women at all stages of their careers. She participated on Goodwin’s behalf in the inaugural Women in Law Hackathon, a competition aimed at generating new ideas to address the gender disparity in the legal industry. Huiya has spoken at numerous legal seminars and appeared on panel presentations sponsored by various organizations, both in the U.S. and internationally.
The George Washington University Law School
University of Massachusetts Amherst
University of Massachusetts Amherst
- New York
- U.S. Patent and Trademark Office (USPTO)
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
- U.S. Court of Appeals for the Federal Circuit
Recognition & Awards
Huiya has been recognized by Patexia’s Top ANDA Litigators in 2020 list.
Huiya was named by IAM Patent 1000 – The World’s Leading Patent Professionals as one of the world’s leading patent litigators, 2016 - 2020.
In 2023, Huiya was recognized among Lawyers of Color's inaugural Wonderful Women, which recognizes dynamic women attorneys working in law firms, companies, and government agencies who show promise in their careers and demonstrate a strong commitment to advancing diversity in the legal profession.
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
- Speaker, “China Pharma: Strategies to Decrease Risk from Third-Party IP,” U.S.-China Intellectual Property Exchange and Development Foundation, April 2021
- Speaker, “US vs China: Goodwin Attorneys Discuss Patent Hurdles and Adalimumab Marketing,” The Center for Biosimilars, February 2021
- Speaker, “An Overview of the Biosimilars Market in China,” Goodwin Webinar, January 2021
- Speaker, “China’s Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?,” Goodwin Webinar (December 2020
- Speaker, “Top of Mind Issues for Global Life Sciences Companies in the Era of COVID-19,” Goodwin Webinar, April 2020
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
- Speaker, “What To Expect in U.S. Litigation on Biosimilars: A Comparison of the BPCIA and the Hatch-Waxman Act,” Webinar, August 2019